KTTA Pasithea Therapeutics Corp.: institutional ownership and insider trading
27 funds reported holding $10.4M of Pasithea Therapeutics Corp. in their latest 13F filings; in Q2 2026 funds net bought $2.05M, with 4 new positions and 0 funds selling out; over the last 12 months insiders bought $203K and sold $0 on the open market.
KTTA revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$5.27M, EPS -0.16
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.87M, EPS -0.12
- Quarter ended Dec 31, 2025: revenue n/a, net income −$10.1M, EPS -0.23
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.04M, EPS -0.41
Famous investors holding KTTA
- Renaissance Technologies (Renaissance Technologies): $33.8K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $33.1K, 0.0% of the portfolio
Largest institutional holders of KTTA
- JANUS HENDERSON GROUP PLC (JHG) — $1.56M
- Cable Car Capital, LP — $1.55M
- Stonepine Capital Management, LLC — $1.13M
- Jupiter Topco LLC — $1.09M
- ADAGE CAPITAL PARTNERS GP, L.L.C. — $1.08M
- Opaleye Management Inc. — $1.06M
- AMERIPRISE FINANCIAL INC (AMP) — $961K
- Squadron Capital Management LLC — $515K
- AdvisorShares Investments LLC — $483K
- Vivo Capital, LLC — $240K
Recent KTTA insider trades
- Jun 17, 2026: Coastlands Capital LP bought 100,000 shares ($53.0K)
- Nov 28, 2025: Steinman Lawrence bought 133,333 shares ($100K)
- Nov 28, 2025: Marques Tiago bought 33,333 shares ($25.0K)
- Nov 28, 2025: Dumesnil Simon bought 33,333 shares ($25.0K)
5%+ owners
- Coastlands Capital LP: 11.5% (Schedule 13G/A, filed Jul 1, 2026)
- Vivo Opportunity Fund Holdings, L.P.: 10.0% (Schedule 13G/A, filed Aug 14, 2026)
- Funicular Funds, LP: 7.4% (Schedule 13G, filed Apr 22, 2026)
- Opaleye Management Inc.: 6.1% (Schedule 13G/A, filed Jul 31, 2026)
- Stonepine Capital Management, LLC: 5.8% (Schedule 13G, filed Jun 23, 2026)
- Ameriprise Financial, Inc.: 5.4% (Schedule 13G/A, filed May 15, 2026)